Calls to action at #NYLCF23: Dr. Luis Paz-Ares asks when can we remove central labs from clinical trials? We need to remove archaic overinterpretation of GCP like signing all labs and creating so many CRFs. New York Lung Cancer Foundation

Cardiologist exci-TED! | NSW Government. Very excited indeed to talk about our research and the need for an additional health/exercise break for all workers ⁦Nepean Blue Mts LHD⁩ ⁦echo@nepean⁩ ⁦ACvA⁩ ⁦NSW CVRN⁩ ⁦Cardiovascular Initiative, University of Sydney⁩ ⁦ nsw.gov.au/health/nbmlhd/…

Today 27 women (half of our 2023 Sydney mentees!) from diverse organisations across the health & medical research ecosystem came together at Macquarie University for their mentee intial workshop 🌟 discussing leadership, inclusion, networks & goals for the 6m ahead 🙌 #WomenInSTEMM

Wow. This is exactly why there should be mandatory crossover when the drug is already SOC in later lines. We are over treating by giving cdk4/6 to everyone 1L. This trial should make news! Bringing common sense back to cancer care! Common Sense Oncology #ASCO23

Interesting to see junior oncologists recommending significantly more chemo vs. senior oncologists ⬆️ experience apparently comes with a trend toward de-escalation of treatment

Come and work with us at the Macquarie University trials unit MQ University Clinical Trials Unit Lots of trials, especially in GU, breast and phase 1. Part-time also considered. Dhanusha Sabanathan Dr Andrew Parsonson Alison Zhang M Crumbaker

Such a privilege to have Bishal Gyawali, MD, PhD, FASCO at Nepean Cancer Care Centre Nepean Blue Mts LHD! Such an inspiration

Honored to present the #OP1250/#palazestrant data at #ESMO23. Encouraging activity in heavily pretreated ER+ pts including >7 mo PFS regardless of ESR1 mut status in 2/3L pts corresponding to EMERALD eligible subset (with elacestrant, median PFS 2.8 mo in all/3.8 mo in ESR1 mut)

Kudos to Dr. Clifton et al for putting together this SABCS23 abstract on the real world toxicity of KN522. 16 sites, 577 pts with TNBC. The KN522 regimen led to a pCR rate of 54%, at the cost of 40% early discontinuations, 11% hospitalization, 54% irAEs, including permanent ones.

A team effort with Anuradha Vasista @brownjlauren Belinda Kiely et al 📝 🙌 simple multiples of the median OS from RCTs can be used to estimate and communicate #prognosis for patients with advanced breast cancer starting endocrine therapy doi.org/10.1111/ajco.1… 🧵 1/X

Median pooled OS over 5 years for MBC on first line ET and CDK4/6 - Dr Andrew Parsonson Anuradha Vasista @brownjlauren Belinda Kiely Macquarie University oncodaily.com/insight/87165.… #Cancer #Cancerawareness #Cancersupport #Cancersupportcommunity #Oncology #Oncodaily #Chemotherapy

‼️📝New Journal of Clinical Oncology publication co-authored by John Park👨🏻‍⚕️🇦🇺 Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a HER2–Directed Antibody-Drug Conjugate, in HER2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I trial MQ University Clinical Trials Unit ➡️ ascopubs.org/doi/10.1200/JC… 🧵1/X

Come and work with us at ⁦MQ University Clinical Trials Unit⁩! Multiple Medical Oncology Fellow positions available for 2025 👇 ⁦Dhanusha Sabanathan⁩ ⁦John Park⁩ ⁦Howard Gurney⁩ linkedin.com/posts/andrew-p…

Come and join us at an information evening 6pm Thursday August 8 if you're interested in Medical Oncology training and would like to join the Nepean-Macquarie-Mater-Orange network. 🍕 and 🥤provided! Info below:

Congratulations to Dr Walid Zwieky and Dr Su Win core medical oncology trainees from the NeMMO training network for presenting their research at #MOGA24 🙌 Dr Deme Karikios Dhanusha Sabanathan John Park Nepean Blue Mts LHD Macquarie University Medical Oncology Group of Australia

Congratulations to Wei Yen and team for latest important advance in ctDNA in neoadjuvant immunotherapy in stage III melanoma 👏👏url.au.m.mimecastprotect.com/s/86RdCBNqgBC7… Melanoma Institute Australia Macquarie Medical School

CSO Webinar announcement! 📣 Register today! Join Dr. Anuradha Vasista and Dr. Deme Karikios as we talk about discussing prognosis with patients living with advanced cancers. The webinar will take place on Zoom on March 19th at 7:00 pm Australian Eastern Daylight Time (8:00 am

Dr Andrew Parsonson presenting his PhD work at Medical Oncology Group of Australia (MOGA) ASM #MOGA25 #Nepeanlegend